Drugs Made In America Acquisition DMAA
NASDAQ DMAA
$10.74 +0.01 (+0.14%)
As of: Aug 21, 2026 · 2:31 PM EDT

Drugs Made In America Acquisition (DMAA) Other financing activities (2025)

Drugs Made In America Acquisition's (DMAA) quarterly Other financing activities came in at $3.2 million in Q1 2025.

Drugs Made In America Acquisition (DMAA) Other financing activities (2025) Analysis & Trends

Drugs Made In America Acquisition (DMAA) has 1 years of Other financing activities data on file, last reported at $3.2 million in Q1 2025.

  • Quarterly Other financing activities changed N/A year-over-year to $3.2 million in Q1 2025, while the trailing twelve-month figure through Dec 2025 was $3.2 million (changed N/A YoY) and the FY2025 annual result came in at $3.2 million, changed N/A from the prior year.
  • Other financing activities held at $3.2 million in Q1 2025.
  • In the past five years, Other financing activities ranged from a high of $3.2 million in Q1 2025 to a low of $3.2 million in Q1 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Oxley Bridge Acquisition 585.76 Mn 585.76 Mn -
2 Launch Two Acquisition 557.86 Mn 557.86 Mn -
3 Drugs Made In America Acquisition 506.00 Mn 506.00 Mn -
4 Cantor Equity Partners IV 468.00 Mn 468.00 Mn -
5 GP-Act III Acquisition 401.06 Mn 401.06 Mn -
6 Aldel Financial 397.49 Mn 397.49 Mn -
7 Republic Digital Acquisition 389.25 Mn 388.51 Mn -
8 Gores Holdings X 385.06 Mn 384.87 Mn -
9 Agriculture & Natural Solutions Acquisition 377.29 Mn 377.04 Mn -
10 Drugs Made In America Acquisition 215.82 Mn 215.82 Mn -

Historic Data

Download Data
DateValue
Mar 31, 2025 3.20 Mn
Mar 31, 2025 3.20 Mn